Last updated on July 2017

Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients


Brief description of study

The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). There will be two groups of patients in the study: the first group will include patients who have never received eculizumab for treatment of PNH. The second group will include patients who have received treatment with eculizumab for at least 6 months prior to the study. Patients will be treated with RA101495 for 12 weeks.

Clinical Study Identifier: NCT03078582

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
North Gosford, New South Wales, Australia
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Parkville, Australia
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Copenhagen, Denmark
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Helsinki, Finland
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Essen, Germany
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Ulm, Germany
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Budapest, Hungary
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Christchurch, New Zealand
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Hamilton, New Zealand
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
Leeds, United Kingdom
  Connect »

Sponsor Ra Pharmaceuticals, Inc.

Investigative Site
London, United Kingdom
  Connect »